|Videos|November 11, 2015

Q&A With Matthew G. Nayor From Brigham & Women's Hospital: Framingham Heart Study Looks At Impact of Carbon Monoxide

The Framingham Heart Study has been one of the most in depth studies in the field of cardiology and medicine as a whole. A recent portion of the study looked at the impact of carbon monoxide exhalation and its role in patient health.

Matthew Nayor, MD, from Brigham & Women's Hospital discussed the results of this study during the annual scientific sessions of the American Heart Association in Orlando.

Join thousands of clinicians staying current on new therapies, trial data, and expert insights—subscribe to HCPLive today.

Related to this article

October 23rd, 2026

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

Jean Elwing, MD, discusses what drove ralinepag's reduction in PAH clinical worsening in ADVANCE Outcomes and where the it could fit if approved.

October 23rd, 2026

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Jean Elwing, MD, discusses a CHEST 2026 subgroup analysis showing ralinepag reduces clinical worsening in PAH even among patients with low-risk criteria.

October 23rd, 2026

Lorundrostat Lowers BP, Albuminuria in CKD With Uncontrolled Hypertension

Lorundrostat cut systolic BP by 9.6 mm Hg and UACR by 52.2% vs placebo in participants with CKD and uncontrolled hypertension in Launch-HTN.

Ashkan Shoamanesh, MD | Image Credit: Academic CME

October 23rd, 2026

Edoxaban Fails to Improve Stroke Risk, Increases Bleeding Risk After Intracranial Hemorrhage

The ENRICH-AF trial ultimately did not demonstrate edoxaban’s efficacy, highlighting the need for further stroke prevention strategies for this patient population.

October 22nd, 2026

AD109 Yields Numerically Greater OSA Improvements in Postmenopausal Women

Reena Mehra, MD, discusses a post hoc analysis in which AD109 reduced AHI4 by 59.6% in postmenopausal women vs 44.0% in non-menopausal participants.

Raed Joundi, MD, DPhil | Image Credit: Population Health Research Institute

October 21st, 2026

Asundexian Safely Reduces Ischemic Stroke Risk Regardless of Infarct Patterns on MRI

A recent MRI analysis of the pivotal OCEANIC-STROKE trial has indicated a complete lack of association between infarct patterns and asundexian’s efficacy.

Xia Wang, MMed | Image Credit: The George Institute

October 21st, 2026

TTR and Systolic Blood Pressure Load Control Improve Recurrent Stroke Risk

A new analysis of 4 major trials has revealed the association between lower SBP and higher TTR and the risk of recurrent stroke after intracerebral hemorrhage.